Progress in the study of the role of spliced X-box-binding protein 1 in autoimmune diseases

doi:10.3877/cma.j.issn.2095-3216.2026.01.005

Abstract

Abstract:

Spliced X-box-binding protein 1 (XBP1s), a core transcription factor in the endoplasmic reticulum stress signaling pathway, regulates protein folding and degradation, influences the functions of immune cells such as B cells, T cells, and dendritic cells, and plays a key role in inflammatory responses and immune-mediated diseases. As such, it has emerged as a potential therapeutic target for autoimmune disorders. Targeted therapeutic strategies against XBP1s, including small-molecule drugs and RNA interference technologies, are currently under development. Targeted therapeutic strategies against XBP1s, including small-molecule drugs and RNA interference technologies, are currently under development. This review summarized the pivotal roles and molecular mechanisms of XBP1s in autoimmune diseases and discussed the application prospect of targeted intervention of XBP1s in the precision therapy of autoimmune diseases.

Key words: Spliced X-box-binding protein 1, Endoplasmic reticulum stress, Autoimmune diseases, Systemic lupus erythematosus, Rheumatoid arthritis

Meijing Pan, Guoshuang Xu. Progress in the study of the role of spliced X-box-binding protein 1 in autoimmune diseases[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2026, 15(01): 29-33.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2026.01.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2026/V15/I01/29

Figures/Tables 1

References 47

[1]	Dumas G, Arabi YM, Bartz R, et al. Diagnosis and management of autoimmune diseases in the ICU [J]. Intensive Care Med, 2024, 50(1)：17-35.
[2]	Merighi A, Lossi L. Endoplasmic reticulum stress signaling and neuronal cell death [J]. Int J Mol Sci, 2022, 23(23): 15186.
[3]	Sano R, Reed JC. ER stress-induced cell death mechanisms [J]. Biochim Biophys Acta, 2013, 1833(12): 3460-3470.
[4]	Szegezdi E, Logue SE, Gorman AM, et al. Mediators of endoplasmic reticulum stress-induced apoptosis [J]. EMBO Rep, 2006, 7(9): 880-885.
[5]	Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress [J]. Nat Cell Biol, 2011, 13(3): 184-190.
[6]	Chen S, Chen J, Hua X, et al. The emerging role of XBP1 in cancer [J]. Biomed Pharmacother, 2020, 127: 110069.
[7]	Garg AD, Kaczmarek A, Krysko O, et al. ER stress-induced inflammation: Does it aid or impede disease progression? [J]. Trends Mol Med, 2012, 18(10): 589-598.
[8]	Xu G, Liu K, Anderson J, et al. Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation [J]. Blood, 2012, 119(18): 4205-4214.
[9]	Bettigole SE, Glimcher LH. Endoplasmic reticulum stress in immunity [J]. Annu Rev Immunol, 2015, 33(1): 107-138.
[10]	So JS. Roles of endoplasmic reticulum stress in immune responses [J]. Mol Cells, 2018, 41(8): 705-716.
[11]	Iwakoshi NN, Lee AH, Vallabhajosyula P, et al. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1 [J]. Nat Immunol, 2003, 4(4): 321-329.
[12]	Park SM, Kang TI, So JS. Roles of XBP1s in transcriptional regulation of target genes [J]. Biomedicines, 2021, 9(7): 791.
[13]	Gass JN, Gifford NM, Brewer JW. Activation of an unfolded protein response during differentiation of antibody-secreting B cells [J]. J Biol Chem, 2002, 277(50): 49047-49054.
[14]	Brucklacher-Waldert V, Ferreira C, Stebegg M, et al. Cellular stress in the context of an inflammatory environment supports TGF-β-independent T helper-17 differentiation [J]. Cell Rep, 2017, 19(11): 2357-2370.
[15]	Stadhouders R, Lubberts E, Hendriks RW. A cellular and molecular view of T helper 17 cell plasticity in autoimmunity [J]. J Autoimmun, 2018, 87: 1-15.
[16]	Pramanik J, Chen X, Kar G, et al. Genome-wide analyses reveal the IRE1a-XBP1 pathway promotes T helper cell differentiation by resolving secretory stress and accelerating proliferation [J]. Genome Med, 2018, 10(1): 76.
[17]	Xiao D, Li S, Gui B, et al. Effect of uremic serum on Th17/Treg cell balance and endoplasmic reticulum stress in rats [J]. Biomed Pharmacother, 2020, 131: 110705.
[18]	Ang Z, Er JZ, Ding JL. The short-chain fatty acid receptor GPR43 is transcriptionally regulated by XBP1 in human monocytes [J]. Sci Rep, 2015, 5(1): 8134.
[19]	Martinon F, Chen X, Lee AH, et al. TLR activation of the transcription factor XBP1 regulates innate immune responses in macrophages [J]. Nat Immunol, 2010, 11(5): 411-418.
[20]	Bettigole SE, Lis R, Adoro S, et al. The transcription factor XBP1 is selectively required for eosinophil differentiation [J]. Nat Immunol, 2015, 16(8): 829-837.
[21]	Iwakoshi NN, Pypaert M, Glimcher LH. The transcription factor XBP-1 is essential for the development and survival of dendritic cells [J]. J Exp Med, 2007, 204(10): 2267-2275.
[22]	Hu F, Yu X, Wang H, et al. ER stress and its regulator X-box-binding protein-1 enhance polyIC-induced innate immune response in dendritic cells [J]. Eur J Immunol, 2011, 41(4): 1086-1097.
[23]	Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis [J]. Cell, 2015, 161(7): 1527-1538.
[24]	Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity [J]. Nat Immunol, 2001, 2(9): 764-766.
[25]	Iwata S, Tanaka Y. B-cell subsets, signaling and their roles in secretion of autoantibodies [J]. Lupus, 2016, 25(8): 850-856.
[26]	Xiang L, Liu A, Xu G. Expression of XBP1s in B lymphocytes is critical for pristane-induced lupus nephritis in mice [J]. Am J Physiol Renal Physiol, 2020, 318(5): F1258-F1270.
[27]	Yap D, Lai K. Pathogenesis of renal disease in systemic lupus erythematosus--the role of autoantibodies and lymphocytes subset abnormalities [J]. Int J Mol Sci, 2015, 16(4): 7917-7931.
[28]	Yap DYH, Chan TM. B cell abnormalities in systemic lupus erythematosus and lupus nephritis-role in pathogenesis and effect of immunosuppressive treatments [J]. Int J Mol Sci, 2019, 20(24): 6231.
[29]	De Luca F, Shoenfeld Y. The microbiome in autoimmune diseases [J]. Clin Exp Immunol, 2019, 195(1): 74-85.
[30]	Navid F, Colbert RA. Causes and consequences of endoplasmic reticulum stress in rheumatic disease [J]. Nat Rev Rheumatol, 2016, 13(1): 25-40.
[31]	Savic S, Ouboussad L, Dickie LJ, et al. TLR dependent XBP-1 activation induces an autocrine loop in rheumatoid arthritis synoviocytes [J]. J Autoimmun, 2014, 50(100): 59-66.
[32]	Corrigall VM, Bodman-Smith MD, Brunst M, et al. Inhibition of antigen-presenting cell function and stimulation of human peripheral blood mononuclear cells to express an antiinflammatory cytokine profile by the stress protein BiP: relevance to the treatment of inflammatory arthritis [J]. Arthritis Rheum, 2004, 50(4): 1164-1171.
[33]	Hu F, Tang Y, Wang P, et al. Endoplasmic reticulum stress perpetuated Toll-like receptor signalling-mediated inflammation in rheumatoid arthritis via X-box-binding protein-1 [J]. Clin Exp Rheumatol, 2021, 39(4): 859-867.
[34]	Piperi C, Adamopoulos C, Papavassiliou AG. XBP1: a pivotal transcriptional regulator of glucose and lipid metabolism [J]. Trends Endocrinol Metab, 2016, 27(3): 119-122.
[35]	Volkmann K, Lucas JL, Vuga D, et al. Potent and selective inhibitors of the inositol-requiring enzyme 1 endoribonuclease [J]. J Biol Chem, 2011, 286(14): 12743-12755.
[36]	Cross BCS, Bond PJ, Sadowski PG, et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule [J]. Proc Natl Acad Sci, 2012, 109(15): E869-E878.
[37]	Mimura N, Fulciniti M, Gorgun G, et al. Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma [J]. Blood, 2012, 119(24): 5772-5781.
[38]	Papandreou I, Denko NC, Olson M, et al. Identification of an IRE1α endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma [J]. Blood, 2011, 117(4): 1311-1314.
[39]	Ri M, Tashiro E, Oikawa D, et al. Identification of toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing [J]. Blood Cancer J, 2012, 2(7): e79.
[40]	Sanches M, Duffy NM, Talukdar M, et al. Structure and mechanism of action of the hydroxy-aryl-aldehyde class of IRE1 endoribonuclease inhibitors [J]. Nat Commun, 2014, 5(1): 4202.
[41]	Wang L, Perera BGK, Hari SB, et al. Divergent allosteric control of the IRE1α endoribonuclease using kinase inhibitors [J]. Nat Chem Biol, 2012, 8(12): 982-989.
[42]	Ji L, Hou X, Deng X, et al. Jieduquyuziyin prescription-treated rat serum suppresses activation of peritoneal macrophages in MRL/lpr lupus mice by inhibiting IRAK1 signaling pathway [J]. Evid Based Complement Alternat Med, 2019, 2019: 2357217.
[43]	Wiseman RL, Zhang Y, Lee KPK, et al. Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of IRE1 [J]. Mol Cell, 2010, 38(2): 291-304.
[44]	Zhou Z, Li A, Wang Z, et al. Blimp-1 siRNA inhibits B cell differentiation and prevents the development of lupus in mice [J]. Hum Immunol, 2013, 74(3): 297-301.
[45]	Chen X, Iliopoulos D, Zhang Q, et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway [J]. Nature, 2014, 508(7494): 103-107.
[46]	Leung-Hagesteijn C, Erdmann N, Cheung G, et al. XBP1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma [J]. Cancer Cell, 2013, 24(3): 289-304.
[47]	Mei Y, Wang X. RNA modification in mRNA cancer vaccines [J]. Clin Exp Med, 2023, 23(6): 1917-1931.

Please choose a citation manager

Content to export